ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable ...
Vistin Pharma ASA (VISTN) will release its first quarter results on Friday 24th of April 2026. Vistin Pharma will host a conference call for all shareholders and interested parties on the same day at ...
COPENHAGEN, Denmark and OSLO, Norway and STOCKHOLM, April 17, 2026 (GLOBE NEWSWIRE) -- The Nordic life science sector is losing highly qualified female talent in top leadership positions, according to ...
YTD Mar 2026 sales AUD$1.3 million up 10% on prior comparative period (pcp) ...
Three world-leading key opinion leaders, researchers and clinicians, join Clinical Advisory Board, reinforcing Bioxodes’ global registrational clinical strategy Positive ongoing discussions with ...
Clermont-Ferrand (France), 17 April 2026 (7:45 am CEST). Carbios (Euronext Growth Paris: ALCRB) today reports operating and financial results for the fiscal-year 2025. The financial statements as of ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC acted as the joint book-running managers for the offering. LifeSci Capital LLC acted as passive bookrunner for the ...
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI are acting as joint book-running managers for the offering. William Blair is acting as lead manager for the offering.
Presentations highlight therapy-induced senescence as a new therapeutic opportunity and reinforce the potential of STX-1 as a differentiated approach for solid tumors Lille and Villejuif, France, ...
In addition to the scientific presentation, SynCardia will exhibit at booth 409, where attendees can learn more about the SynCardia Total Artificial Heart and ongoing efforts to expand access to life ...
Sanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1. EDEN PRAIRIE, Minn., April 16, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results